Form 4: Progyny Director Cohen Fred E. Reports Stock Option Grant and RSU Vesting

Director Cohen Fred E. of Progyny, Inc. reports the acquisition of stock options and restricted stock units (RSUs) on May 23, 2024.

Summary

• On May 23, 2024, Fred E. Cohen, a director of Progyny, Inc., reported transactions involving the company's stock.
• Cohen acquired 6,176 shares of common stock underlying restricted stock units (RSUs).
• These RSUs will vest on May 23, 2025, contingent upon continued service.
• Cohen also acquired options to purchase 25,070 shares of common stock at an exercise price of $27.15.
• These options will vest on May 23, 2025, also contingent upon continued service.
• Following these transactions, Cohen directly owns 22,693 shares of Progyny common stock and 25,070 stock options.

Sentiment

Score: 6

Explanation: The document reflects standard insider transactions, suggesting a neutral sentiment. The vesting of equity indicates a positive outlook from the director's continued service.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of RSUs and stock options is contingent upon the Reporting Person's continued service, indicating an expectation of continued involvement with the company.

Industry Context

This filing is a routine disclosure of insider transactions, common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders, which can be informative for investors.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of compensation for directors in publicly traded companies like Progyny.
• The vesting schedules, typically tied to continued service, are also standard practice.
• Companies like Teladoc Health and Accolade, which operate in related healthcare technology sectors, also utilize similar equity-based compensation strategies for their directors and executives.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding director compensation and alignment of interests.

Key Dates